Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 39 articles: HTML format

Single Articles

September 2023
1. CHARVAT H, Fukui K, Matsuda T, Katanoda K, et al
   Impact of cancer and other causes of death on mortality of cancer patients: A study based on Japanese population-based registry data.
   Int J Cancer. 2023;153:1162-1171.
   PubMed     Abstract available
   
   
   
2. SALACHAN PV, Rasmussen M, Ulhoi BP, Jensen JB, et al
   Spatial whole transcriptome profiling of primary tumor from patients with metastatic prostate cancer.
   Int J Cancer. 2023 Sep 1. doi: 10.1002/ijc.34708.
   PubMed     Abstract available
   
   
   August 2023
3. HUERTAS-LAREZ R, Munoz-Moreno L, Recio-Aldavero J, Roman ID, et al
   Induction of more aggressive tumoral phenotypes in LNCaP and PC3 cells by serum exosomes from prostate cancer patients.
   Int J Cancer. 2023 Aug 1. doi: 10.1002/ijc.34673.
   PubMed     Abstract available
   
   
   June 2023
4. LIU H, Shui IM, Keum N, Shen X, et al
   Plasma total cholesterol concentration and risk of higher-grade prostate cancer: A nested case-control study and a dose-response meta-analysis.
   Int J Cancer. 2023 Jun 12. doi: 10.1002/ijc.34621.
   PubMed     Abstract available
   
   
   May 2023
5. CHAN JSK, Lee YHA, Hui JMH, Liu K, et al
   Long-term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population-based competing risk analysis.
   Int J Cancer. 2023 May 14. doi: 10.1002/ijc.34557.
   PubMed     Abstract available
   
   
   
6. LEHTO TK, Kovanen RM, Lintula S, Malen A, et al
   Prognostic impact of kallikrein-related peptidase transcript levels in prostate cancer.
   Int J Cancer. 2023 May 4. doi: 10.1002/ijc.34551.
   PubMed     Abstract available
   
   
   March 2023
7. 
   Erratum to "Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial".
   Int J Cancer. 2023 Mar 20. doi: 10.1002/ijc.34484.
   PubMed    
   
   
   
8. ZHOU T, Qin S, Xu W, Tang S, et al
   Proxalutamide in metastatic castration-resistant prostate cancer: primary analysis of a multicenter, randomized, open-label, phase 2 trial.
   Int J Cancer. 2023 Mar 15. doi: 10.1002/ijc.34512.
   PubMed     Abstract available
   
   
   February 2023
9. KLUSA D, Lohaus F, Franken A, Baumbach M, et al
   Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy.
   Int J Cancer. 2023 Feb 2. doi: 10.1002/ijc.34457.
   PubMed     Abstract available
   
   
   January 2023
10. LILLEBY W, Seierstad T, Inderberg EM, Hole KH, et al
    Impact of hTERT peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
    Int J Cancer. 2023 Jan 30. doi: 10.1002/ijc.34448.
    PubMed     Abstract available
    
    
    
11. LI Y, Zheng R, Zhang Y, Huang C, et al
    Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
    Int J Cancer. 2023;152:42-50.
    PubMed     Abstract available
    
    
    December 2022
12. CATTRINI C, Messina C, Mennitto A, Di Maio M, et al
    Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)".
    Int J Cancer. 2022;151:2291-2292.
    PubMed    
    
    
    
13. WEI C, Chen X, Ji J, Xu Y, et al
    UE-PSA is a non-invasive biomarker to detect prostate cancer: not only old wine in new bottles.
    Int J Cancer. 2022 Dec 1. doi: 10.1002/ijc.34388.
    PubMed     Abstract available
    
    
    November 2022
14. CHEN HK, Su PJ, Wang YL, Chang KC, et al
    Long Term Use and Risk of Major Adverse Cardiac Events: Comparing Enzalutamide and Abiraterone in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34348.
    PubMed     Abstract available
    
    
    September 2022
15. KRILAVICIUTE A, Albers P, Lakes J, Radtke JP, et al
    Adherence to a risk-adapted screening strategy for prostate cancer - first results of the PROBASE trial.
    Int J Cancer. 2022 Sep 19. doi: 10.1002/ijc.34295.
    PubMed     Abstract available
    
    
    
16. WU J, Tan X
    The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
    Int J Cancer. 2022;151:888-896.
    PubMed     Abstract available
    
    
    
17. OLA IO, Talala K, Tammela T, Taari K, et al
    Prostate cancer incidence in men with Prostate-Specific Antigen (PSA) below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
    Int J Cancer. 2022 Sep 2. doi: 10.1002/ijc.34274.
    PubMed     Abstract available
    
    
    August 2022
18. JAMES ND, Clarke NW, Cook A, Ali A, et al
    Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
    Int J Cancer. 2022;151:422-434.
    PubMed     Abstract available
    
    
    July 2022
19. CARM KT, Johannessen B, Bogaard M, Bakken AC, et al
    Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer.
    Int J Cancer. 2022 Jul 26. doi: 10.1002/ijc.34226.
    PubMed     Abstract available
    
    
    
20. OSTMAN JR, Pinto RC, Ebbels TM, Thysell E, et al
    Identification of pre-diagnostic metabolites associated with prostate cancer risk by untargeted mass spectrometry-based metabolomics: A case-control study nested in the Northern Sweden Health and Disease Study.
    Int J Cancer. 2022 Jul 22. doi: 10.1002/ijc.34223.
    PubMed     Abstract available
    
    
    
21. GEDEBORG R, Loeb S, Styrke J, Kiiski-Berggren R, et al
    Susceptibility to SARS-Cov-2 Infection and Risk for Severe COVID-19 in Patients with Prostate Cancer on Androgen Deprivation Therapy.
    Int J Cancer. 2022 Jul 8. doi: 10.1002/ijc.34204.
    PubMed     Abstract available
    
    
    June 2022
22. CSIZMARIK A, Keresztes D, Nagy N, Bracht T, et al
    Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
    Int J Cancer. 2022 Jun 11. doi: 10.1002/ijc.34159.
    PubMed     Abstract available
    
    
    May 2022
23. WATTS EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, et al
    Circulating free testosterone and risk of aggressive prostate cancer: prospective and Mendelian randomization analyses in international consortia.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34116.
    PubMed     Abstract available
    
    
    April 2022
24. FORSTER RB, Engeland A, Kvale R, Hjellvik V, et al
    Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in non-metastatic prostate cancer.
    Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34058.
    PubMed     Abstract available
    
    
    
25. MATSUSHITA M, Fujita K, Hatano K, Hayashi T, et al
    High-fat diet promotes prostate cancer growth through histamine signaling.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34028.
    PubMed     Abstract available
    
    
    
26. CONTEDUCA V, Scarpi E, Wetterskog D, Brighi N, et al
    Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.
    Int J Cancer. 2022;150:1166-1173.
    PubMed     Abstract available
    
    
    March 2022
27. DIAZ DE LA GUARDIA-BOLIVAR E, Barrios-Rodriguez R, Zwir I, Jimenez-Moleon JJ, et al
    Identification of novel prostate cancer genes in patients stratified by Gleason classification: role of antitumoral genes.
    Int J Cancer. 2022 Mar 2. doi: 10.1002/ijc.33988.
    PubMed     Abstract available
    
    
    January 2022
28. ARSOV C, Albers P, Herkommer K, Gschwend J, et al
    A Randomized Trial of Risk-Adapted Screening for Prostate Cancer in Young Men - Results of the First Screening Round of the PROBASE Trial.
    Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33940.
    PubMed    
    
    
    
29. FAN Z, Ma J, Pan X, Zhao L, et al
    Crosstalk of FGFR1 signaling and choline metabolism promotes cell proliferation and survival in prostate cancer cells.
    Int J Cancer. 2022 Jan 5. doi: 10.1002/ijc.33922.
    PubMed     Abstract available
    
    
    December 2021
30. DJAMGOZ MBA
    Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33890.
    PubMed    
    
    
    
31. SALMINEN JK, Murtola TJ
    Reply to Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33887.
    PubMed    
    
    
    October 2021
32. PAYNE H, Robinson A, Rappe B, Hilman S, et al
    A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.
    PubMed     Abstract available
    
    
    
33. LI X, Cheng K, Li X, Zhou Y, et al
    Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.
    Int J Cancer. 2021;149:1473-1482.
    PubMed     Abstract available
    
    
    September 2021
34. LIU D, Zhu J, Zhou D, Nikas EG, et al
    A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk.
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33808.
    PubMed     Abstract available
    
    
    July 2021
35. KOSTOS L, Hong W, Lee B, Tran B, et al
    Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting.
    Int J Cancer. 2021;149:409-419.
    PubMed     Abstract available
    
    
    April 2021
36. RASPIN K, FitzGerald LM, Marthick JR, Field MA, et al
    A rare variant in EZH2 is associated with prostate cancer risk.
    Int J Cancer. 2021 Apr 6. doi: 10.1002/ijc.33584.
    PubMed     Abstract available
    
    
    February 2021
37. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available
    
    
    September 2020
38. WEITZER J, Castano-Vinyals G, Aragones N, Gomez-Acebo I, et al
    Effect of time of day of recreational and household physical activity on prostate and breast cancer risk (MCC-Spain Study).
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33310.
    PubMed     Abstract available
    
    
    August 2020
39. BADRISING SK, Louhanepessy RD, van der Noort V, Coenen JLLM, et al
    A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
    Int J Cancer. 2020;147:1143-1151.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: